Small Molecule Innovator API CDMO Market To Reach $47.14 Billion By 2030

Small Molecule Innovator API CDMO Market Growth & Trends

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

 Request a free sample copy or view report summary: Small Molecule Innovator API CDMO Market Report

Small Molecule Innovator API CDMO Market Report Highlights

• The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth

• Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases

• The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment

• Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure

Small Molecule Innovator API CDMO Market Segmentation

Grand View Research has segmented the global small molecule innovator API CDMO market based on stage type, customer type, therapeutic area, and region:

Small Molecule Innovator API CDMO Stage Type Outlook (Revenue, USD Million, 2018 - 2030)

• Preclinical

• Clinical

  • Phase I

  • Phase II

  • Phase III

• Commercial

Small Molecule Innovator API CDMO Customer Type Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical

  • Small

  • Medium

  • Large

• Biotechnology

  • Small

  • Medium

  • Large

Small Molecule Innovator API CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Cardiovascular Diseases

• Oncology

• Respiratory Disorders

• Neurology

• Metabolic Disorders

• Infectious Diseases

• Others

Small Molecule Innovator API CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

  • Taiwan

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Israel

List of Key Players in Small Molecule Innovator API CDMO Market

• Lonza Group Ltd.

• Novo Holdings (Catalent, Inc.)

• Thermo Fisher Scientific, Inc.

• Siegfried Holding AG

• Recipharm AB

• CordenPharma International

• Samsung Biologics

• Labcorp

• Ajinomoto Bio-Pharma Services

• Piramal Pharma Solutions

• Jubilant Life Sciences (Jubilant Biosys Limited)

• WuXi AppTec Co., Ltd.